企業プロフィール
Aclarion 株価・ニュース・カタリスト
- ティッカー:
- ACON
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
2.71 USD (+0.74%)
終値
最終更新: 2026年8月21日
8.62M USD
時価総額
株価変動の要因
Following the latest company update, “Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site”, ACON closed down 2.89% at $2.69 on Aug 20, 2026. The move occurred in the trading session associated with this clinical readout update.
企業概要
Chronic Low-Back-Pain Diagnostics
Aclarion develops technology to help physicians identify which lumbar discs may be generating chronic low-back pain. Its approach combines magnetic resonance spectroscopy, biochemical biomarkers, signal processing and augmented-intelligence algorithms.
Nociscan Platform
Nociscan is a software-as-a-service platform that analyzes disc chemistry noninvasively and classifies discs as more likely painful or nonpainful. Physicians use the information alongside imaging and other diagnostic tools when selecting treatment targets.
Evidence and Reimbursement Strategy
Aclarion is supporting Nociscan with multiple clinical and real-world evidence studies. The evidence program is intended to demonstrate treatment-selection value and establish commercial-insurance coverage pathways.
今後のカタリスト
- Preliminary internal CLARITY trial readout expected in the second half of 2026.
- Public disclosure of early interim CLARITY results anticipated in the fourth quarter of 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。